---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-121019"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T22:02:47.648292+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA cuts workforce ~80%, pauses eseba-vec HPV16+ trial, focuses on HB-700

## Summary
- Workforce reduction of ~80%; implementation begins Q4 2024, substantially complete by H1 2025.
- Pauses eseba-vec program; early termination of Phase 1/2 trial for HPV16+ head and neck cancers (not due to safety or efficacy).
- Focuses on phase 1-ready HB-700 for KRAS mutated cancers (lung, colorectal, pancreatic); FDA IND clearance received Apr 2024.
- Continues HB-500 (HIV) Phase 1b trial and HB-400 (Hepatitis B) program with partner Gilead.
- Will seek partnering opportunities for the eseba-vec program.

## SEC filing metadata
- accession: 0001104659-24-121019
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465924121019/0001104659-24-121019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465924121019/tm2429040d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-121019
- JSON: https://secwatch.observer/filing/0001104659-24-121019.json
- Plain text: https://secwatch.observer/filing/0001104659-24-121019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.